




I'm not robot



**Continue**

## Myocardial infarction made easy

(Guide) Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr., Ganiats TG, Holmes DR Jr., et al 2014 AHA/ACC Guide to Managing Patients with Non-ST-Height Acute Coronary Syndromes: Report by the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014 Dec 23. 130 (25):e344-426. (Medline), (Full text). (Guide) O'Gara PT, Kushner FG, Ascheim DD, et al American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA Guide to Managing ST-Height Myocardial Infarction: A report by the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013 Jan 29. 127 (4):e362-425. (Medline), (Full text). (Guide) Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the Treatment of Acute Coronary Syndromes in Patients, Presenting Non-Resistant ST-Segment Heights: Target Group for The Management of Acute Coronary Syndromes in Patients, presenting an unslyly ST-segment of the rise of the European Society of Cardiology (ESC). *Eur Heart J*. 2016 Jan 14. 37 (3):267-315. (Medline), (Full text). (Guide) Task Force for the management of the ST-segment of the high level of acute myocardial infarction of the European Society of Cardiology (ESC); Steg PG, James SK, Atar D and others ESC Guidelines for the Management of Acute Myocardial Infarction in patients present with ST-segment height. *Eur Heart J*. 2012 Oct 33 (20):2659-619. (Medline), (Full text). Costa e Silva R, Pellanda L, Portal V, Maciel P, Furquim A, Schaan B. Transdisciplinary approach to subsequent treatment of patients after myocardial infarction. *Clinics (Sao Paulo)*. 2008 Aug. 63 (4):489-96. (Medline) Rathor SS, Gersh BJ, Weinfurt KP, Oetgen WJ, Shulman K.A., Solomon AJ. The role of reperfusion therapy in patients with acute myocardial infarction. *Am Heart J*. 2001 Sep. 142(3):516-9. (Medline). Jaffe AS. The third universal definition of myocardial infarction. *Wedge Biohim*. 2013 January 46 (1-2):1-4. (Medline). Bonaca MP, Wiviott SD, Braunwald E, et al. American College of Cardiology/American Heart Association/European Heart Society/World Heart Federation Universal Definition of Myocardial Infarction Classification System and Cardiovascular Death Risk: Observations from TRITON-TIMI 38 Trial (Trial to assess the improvement of therapeutic outcomes by optimizing blood clot inhibition with prasugr (Medline). Tigesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. *J Am Coll Cardiol*. 2012 Oct 16. 60 (16):1561-98. (Medline). Fujita M, Nakae I, Kihara Y, et al. Determinants of concomitant development in patients with acute myocardial infarction. *Wedge Cardiol*. 1999 September 22 (Medline). Birchfield JS, Se M, Hill JA. Pathological ventricular remodeling: mechanisms: part 1 of 2. *Circulation*. 2013 July 23. 128 (4):388-400. (Medline). Yellon DM, Hausenla DJ. Trauma of myocardial rechecking. *N Engl J Med*. 2007 Sep 13. 357 (11):1121-35. (Medline). Marban E. Myocardial is terrific and hibernating. The physiology behind the conversations. *Circulation*. 1991 February 83 (2):681-8. (Medline). McGill HC Jr., McMahan CA, Siske AW, et al Association of Risk Factors for Coronary Heart Disease with Intermediate Atherosclerosis In Youth. Pathobiological determinants of Atherosclerosis in Youth (PDAY) Research Group. *Atherosclerosis Thromb Vasc Biol*. 2000 Aug 20 (8):1998-2004. (Medline). Wells FD, Virmani R, Burke AP, et al. Pathological assessment of a vulnerable coronal plaque of a person. *Heart*. 2004 December 90 (12):1385-91. (Medline). Soares AAS, TavoniTM, de Faria EC, Remalay AT, Maranhao RC, Sposito AC, etd. *Wedge Chim Acta*. 2018 March 478:51-6. (Medline). Holmes MV, Millwood IV, Kartsonaki C, et al. for China Kadoorie Biobank Joint Group. Lipids, lipoproteins and metabolites, as well as the risk of heart attack and stroke myocardial. *J Am Coll Cardiol*. 2018 Feb 13. 71 (6):620-32. (Medline). (Full text). Chatzizisis VS, Coskun AU, Jonas M, Edelman ER, Feldman CL, Stone PH. The role of endothelial stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular and vascular behavior. *J Am Coll Cardiol*. 2007 June 26. 49(25):2379-93. (Medline). Van JC, Normand SL, Mauri L, Kuntz RE. Spatial distribution of coronary arteries in acute heart attacks myocyluses myocardia. *Circulation*. 2004 July 20. 110(3):278-84. (Medline). Falk E, Shah PC, Fuster V. Coronary plaque breach. *Circulation*. 1995 Aug 1. 92(3):657-71. (Medline). McDaniel MC, Willis P, Walker B, et al. The content of the necrotic nucleus plaque is more directly distic for bifurcation compared to bifurcation in proximal guy patients with CAD. *Am J Cardiol*. 2008. 102(8):242i. Yusuf S, Hawken S, Ounpuu S, et al., for interHEART investigators investigation. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (INTERHEART study): case control study. *Lancet*. 2004 September 11-17. 364 (9438):937-52. (Medline). Macintyre CR, Heywood AE, Kovoop P, et al. Ishaemic Heart Disease, Influenza and Influenza Vaccination: a promising study to control cases. *Heart*. 2013 December 99 (24):1843-8. (Medline). Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction after a laboratory-confirmed flu infection. *N Engl J Med*. 2018 Jan 25. 378 (4):345-53. (Medline), (Full text). Conchiro-Gisan A., S., Fernandez-Santamarina I, Gonzalez-Carrero J. J. heart attack: an unexpected diagnosis in the parent room. *Fetal pediatric Patol*. 2006 July-August. 25(4):179-84. (Medline). Rogers WJ, Frederick PD, Stoehr E, et al. Trends in performance and hospital mortality among patients with increased ST and non-ST increase in myocardial infarction in the National Myocardial Infarction Registry from 1990 to 2006. *Am Heart J*. 2008 December 156 (6):1026-34. (Medline). Lloyd-Jones D, Adams RJ, BrownTM, et al., for the American Heart Association Statistics Committee and subcommittee on stroke statistics. Summary: Statistics of Cardiovascular Disease and Stroke-2010 Update: Report by the American Heart Association. *Circulation*. 2010 Feb 23. 121 (7):948-54. (Medline). Levi F, Lucchini F, Negri E, La Vecchia C. Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other regions of the world. *Heart*. 2002 Aug. 88 (2):119-24. (Medline). Critchley J, Liu J, zhao D, Wei W, Capewell S. Explaining the increase in deaths from coronary heart disease in Beijing between 1984 and 1999. *Circulation*. 2004, September 7. 110 (10):1236-44. (Medline). Reddy COP. Cardiovascular disease in non-Western countries. *N Engl J Med*. 2004 June 10. 350 (24):2438-40. (Medline). Okrainec K, Banerjee DK, Eisenberg MJ. Ischemic heart disease in developing countries. *Am Heart J*. 2004 July. 148 (1):7-15. (Medline). Ezzati M. How can inter-state health risk studies enhance interventions? Lessons from INTERHART. *Lancet*. 2004 September 11-17. 364 (9438):912-4. (Medline). Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papucis G. TIMI Risk Assessment for Unstable Angina/non-ST HEIGHT MI: Forecasting Method and Therapeutic Decision Decision. *Jama*. 2000 Aug 16. 284(7):835-42. (Medline). Jaber WA, Prior DL, Marceau SP, Houghtaling PL, Menon V, Harrington RA. The CHF presentation is associated with noticeably worse results among patients with acute coronary syndromes: PURSUIT test results. *Circulation* 1999;100 (suppl 1): I-433. Killip T 3rd, Kimball JT. Treatment of myocardial infarction in the coronary care department. Two years of experience with 250 patients. *Am J Cardiol*. 1967 Oct 20(4):457-64. (Medline). James SC, Lindahl B, Sigban A, et al. N-terminal pro-brain natriuretic peptide and other markers of risk for separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary heart disease: the global use of strategies for opening closed arteries (GUSTO)-IV satrindion. *Circulation*. 2003 July 22. 108 (3):275-81. (Medline). de Lemos JA, Morrow DA, Bentley JH, et al. Predictive value of type B natriuretic peptide in patients with acute coronary syndromes. *N Engl J Med*. 2001 Oct 4. 345 (14):1014-21. (Medline). Haaf., Reichlin T, Corson N, et al. B-type natriuretic peptide in early diagnosis and risk of stratification of acute chest pain. *Am J* 2011 May. 124 (5):444-52. (5):444-52. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a powerful predictor of mortality regardless of and in combination with troponin T in acute coronary syndrome: TIMI 11A, thrombolysis in myocardial infarction. *J Am Coll Cardiol*. 1998 June 31 (7):1460-5. (Medline). Boggs V. Worst prognosis for patients with myocardial infarction with ST-deviation in AVR. *Medswipe*. July 11, 2013. (Full text). Alherbish A, Westerhut CM, Fu Y, et al. Forgotten Lead: does AVR ST-deviation add insight into the results of ST-height myocardial infarction patients?. *Am Heart J*. Jul 3 2013. (Full text). Lee KL, Woodlief LH, Topol EJ, et al., for GUSTO-I investigators. Predictors of 30-day mortality in the era of reperfusion in acute myocardial infarction. The results of an international study of 41,021 patients. GUSTO-I Investigators. *Circulation*. 1995, March 15. 91 (6):1659-68. (Medline). (Guide) Smith SC Jr., Allen J, Blair SN, et al. AHA/ACC Guidelines for Secondary Prevention of Patients with Coronary and Other Atherosclerotic Vascular Diseases: 2006 Update: Approved by the National Heart, Lung and Blood Institute. *Circulation*. 2006 May 16. 113 (9):2363-72. (Medline). (Full text). Mann DL, Sips DP, Libby P, Bonow RO, Brownwald E, eds. *Brownwald E, Guide. Brownwald E, Guide. A textbook of cardiovascular medicine*. 10th o. Philadelphia, PA: Elsevier Saunders; 2015. Wijnbergen I, Van't Veer M, Pijls NH, Tijssen J. Circadian and the weekly changes and effects of environmental variables in acute myocardial infarction. *Neth Heart J*. 2012 Sep. 20 (9):354-9. (Medline). Kundi H, Kyzyltun E, Korkmaz A, Chichek G, Ornek E, Ileri M. New risk assessment system for predicting cardiovascular death in patients with acute myocardial infarction: CHA2DS2-VASc-CF score. *Wedge Apple Tromb Hemost*. 2018 March 24 (2):273-8. (Medline). Kacprzak M, Kidawa M, Selinski M. Fever in myocardial infarction: it's still common, is it still predictive?. *Cardiol J*. 2012. 19 (4):369-73. (Medline). Rice C, Kirkebi OJ, Gretum., Sederholm M, Kyekshus JK. Fever after acute myocardial infarction in patients, treatment with intravenous thymolol or placebo. *Br Heart J*. 1987 Jan. 57 (1):28-31. (Medline). Patel MR, Mahaffey KW, Armstrong PW, Weaver WD, Tassa G, Hochman JS, et al. Predictive usefulness of white blood cell analysis and temperature in acute myocardial infarction (from CARDINAL Trial). *Am J Cardiol*. 2005 March 1. 95 (5):614-8. (Medline). Lee-Lewandowski E., Januzzi JL Jr., Grisson R, Mohammed A.A., Lewandrowski G, Lewandrowski K. Grade first draw all the blood, the point of cardiac marker care in the context of the universal definition of myocardial infarction: comparing the multimarkers of the troponin panel alone and testing in the central laboratory. *Apka Pathol Lab Med*. 2011 April 135 (4):459-63. (Medline). Apple FS. New season for heart tests Indicators. *Wedge Chem*. 2009 July 55 (7):1303-6. (Medline). Dirks DB, Peacock WF 4, Hollander JE, et al. Diagnostic accuracy of troponin at the point of care I analysis for acute myocardial infarction within 3 hours after presenting the early presenters to the emergency room with chest pain. *Am Heart J*. 2012 Jan. 163 (1):74-80.e4. (Medline). Takakuwa KM, U FS, Peterson ED, et al. Using models of cardiac bedside markers using point-of-care testing for troponin in a non-ST-segment height acute coronary syndrome: CRUSADE results. *Wedge Cardiol*. 2009 Sep. 32 (9):498-505. (Medline). Muller C. Biomarkers and Acute Coronary Syndromes: Update. *Eur Heart J*. 2001 March 35 (9):552-6. (Medline). Anderson JL, Adams CD, Antman EM, et al., for ACC, AHA Task Force on Practice Guidelines (Letter of the Review Committee 2002 Guidelines for The Management of Patients with Unstable Angina/NSTEMI), et al. ACC/AHA 2007 Guidelines for Patient Management with unstable angina/not ST-height myocardial infarction: report by the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Letter to the Committee for the Review of 2002 Guidelines for The Management of Patients with Unstable Angina/ Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Surgery and Intensity... *Circulation*. 2007 Aug 14. 116 (7):e148-304. (Medline). Reichlin T, Irfan A, Tverenbold R, et al. Usefulness of absolute and relative changes in troponin concentration in early diagnosis of acute myocardial infarction. *Circulation*. 2011 July 12. 124(2):136-45. (Medline). Storror AB, Novak RM, Dirks DB, et al. Absolute and relative changes (delta) in troponin I for early diagnosis of myocardial infarction: Results of a prospective multicenter study. *Wedge Biohim*. 2015 March 48 (4-5):254-9. (Medline). Cullen L, Parsonage WA, Greenslade J, et al Delta troponin for early diagnosis of AMI in ambulance patients with chest pain. *Its J Cardiol*. 2013 Oct 3. 168 (3):2602-8. (Medline). Thygesen K, Mair J, Muller C, et al., for the research group on biomarkers in cardiology ESC Working Group on Acute Cardiology Care. Recommendations for the use of natriuretic peptides in acute cardiac care: a statement of the research group on biomark in cardiology of the ESC Working Group on Emergency Cardiology. *Eur Heart J*. 2012 Aug 33 (16):2001-6. (Medline). Goldstein JA, Chinmayan KM, Abboud A, et al. for CT-STAT CT-STAT (Coronary Computed Tomographic Angiography for Systematic Systematic acute chest pain of patients to treat trial). *J Am Coll Cardiol*. 2011 September 27. 58 (14):1414-22. (Medline). Samad S, Hakim A., Mahmoud SS, etc. Meta-analysis and systematic review of computed tomography as a diagnostic sorting tool for patients with chest pain submitted to the emergency department. *J Nucl Cardiol*. 2012 Apr 19 (2):364-76. (Medline). Kremer PC, Khalaf S, Agarwal S, et al. Microdialysis images in emergency room patients with negative cardiac biomarkers: output to detect ischemia, short-term events, and the effect downstream of revascularization on mortality. *Circus Cardiovasc Images*. 2014 November 7 (6):912-9. (Medline). Amgen Inc. FDA approves Repatha Amgen (evolocumab) to prevent heart attack and stroke (press release). Available by, December 1, 2017; Access: December 7, 2017 Sabatin MS, Giugliano RP, Keech AH, et al., for FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. 2017 May 4. 376 (18):1713-22. (Medline), (Full text). Becker L, Larsen MP, Eisenberg MS. Incidence of cardiac arrest during self-transport for chest pain. *Ann Emerg Med*. 1996 Dec 28 (6):612-6. (Medline). Matthews R, Peterson ED, Lee S, et al. Use of Emergency Transportation Care among patients with ST-segment-height myocardial infarction: findings from the National Registry of Cardiovascular Data Sharp Coronary Interventions Network Results Registry-Get with Guidelines. *Circulation*. 2011 July 12. 124 (2):154-63. (Medline). (Guide) Jneid H, Addison D, Bhatt DL, et al. 2017 AHA/ACC Clinical Indicators and Performance Indicators for Adults with ST-Height and Non-ST-Height Myocardial Infarction: Report by the American College of Cardiology/American Heart Association Performance Task Force. *J Am Coll Cardiol*. 2017 Oct 7. 70 (16):2048-90. (Medline). Wendling P. AHA IACC to release new performance indicators, quality indicators for MI. *Medscape Medical News*. Available by, September 22, 2017; Access: March 26, 2018 (Medline) Ibanez B, James S, Agewall S, et al., for ESC Scientific Group Documents. 2017 ESC guidelines for managing acute myocardial infarction in patients, presenting with ST-segment height: Task Force on the management of acute myocardial infarction in patients, presenting with the ST-segment height of the European Society of Cardiology (ESC). *Eur Heart J*. 2018 Jan 7. 39 (2):119-77. (Medline), (Full text). Cabello JB, Burls A, Emparanza JI, Bayliss S, Quinn T. Oxygen Therapy acute myocardial infarction. *Cochrane Database Rev*. 2013 Aug 21. 8:CD007160. (Medline). Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or associated with the use of selective inhibitors of cyclooxygenase-2 and non-selective non-steroidal anti-inflammatory drugs after acute myocardial infarction. *Circulation*. 2000 June 27. 113 (25):2906-13. (Medline). Luepker VR, Raczynski JM, Osganian S, et al. Effect of community intervention on patient delay and the use of emergency medical care in acute coronary heart disease: Rapid Early Action for Coronary Treatment (REACT) Trial. *Jama*. 2000, July 5. 284 (1):60-7. (Medline). De Luca G, Suryapratnata H, Otterwanger JP, Antman EM. Delay in treatment time and mortality in primary angioplasty in acute myocardial infarction: every minute of delay is counted. *Circulation*. 2004 March 16. 109 (10):1223-5. (Medline). Armstrong PW, Westerhout CM, Welsh RC. The duration of symptoms is a key modulator of reperfusion choice for ST-height myocardial infarction. *Circulation*. 2009 March 10. 119 (9):1293-303. (Medline). Bates ER, Nallamothu BK. Comment: the role of percutaneous coronary intervention in ST-segment-height myocardial infarction. *Circulation*. 2008 July 29. 118 (5):567-73. (Medline). Ellis SG, Armstrong P, Betriu A, et al., for facilitated intervention with increased reperfusion speed to stop the events of investigators. Lightweight percutaneous coronary intervention compared to primary percutaneous coronary intervention: the development and justification of a lightweight intervention with an increased rate of reperfusion to stop the event (FINESSE) trial. *Am Heart J*. 2004 Apr 147 (4):E16. (Medline). Andersen HR, Nielsen TT, Rasmussen S, et al., for DANAMI-2 investigators. Comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. *N Engl J Med*. 2003 Aug 21. 349 (8):733-42. (Medline). Vidimsky., Budesensky T., Vorak D, et al. for investigators of the PRAGUE research team. Long-distance transport for primary angioplasty against immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicenter study --PRAGUE-2. *Eur Heart J*. 2003 Jan. 24 (1):94-104. (Medline). Vaidya SR, Samar A, Arora S, Devarapally SR, Condur A, Kaul. The culprit against multi-month coronary intervention in the ST segment of myocardial infarction: a meta-analysis of randomized trials. *Crown Arteria Dis*. 2018 March 29 (2):151-60. (Medline). Spitaleri G, Brugaletta S, Scalone G and others The st-segment resolution role in patients with ST-segment myocardial infarction, which is treated with primary percutaneous coronary intervention (of the 5-year examination test results). *Am J Cardiol*. February 7, 2018. (Full text). Rencusogullari I, Kagdas M., Karabag I, et al Association SYNTAX Grade II with heart rupture in patients with ST-segment myocardial infarction height undergoes primary percutaneous coronary intervention. *Crown Arteria Dis*. 2018 March 29 (Medline). Trialists' Fibrinolytic Therapy (FTT) Collaboration Investigators for fibrinolytic therapy for suspected acute myocardial infarction: a joint review of early mortality and underlying morbidity outcomes from all randomized trials of more than 1,000 patients. *Lancet*. 1994 Feb 5. 343 (8893):311-22. (Medline). White HD. Thrombolytic therapy in the elderly. *Lancet*. 2000 Dec 16. 356 (9247):2028-30. (Medline). Van de Werf F, Barron HV, Armstrong PW, et al. for ASSENT-2 investigators. Assess the safety and efficacy of the new thrombolytic. Incidence and predictors of bleeding after fibrinolytic therapy with fibrin-specific agents: comparison of TNK-TPA and r-PA. *Eur Heart J*. 2001 December 22 (24):2253-61. (Medline). Kudumuri V, Balasubramanian S, Vig A, et al. Meta-analysis comparing percutaneous coronary intervention with the drug eluting stent compared to coronary artery bypassing in the unprotected left underlying disease (in the press). *Am J Cardiol*. February 5, 2018. (Full text). Yusuf S, Mehta SR, Chrolavicius S, et al. for oasis-6 Trial Group. Effect of fondaparinux on mortality and overwork in patients with acute ST-segment high-altitude myocardial infarction: randomized study OASIS-6. *Jama*. 2006 Apr 5. 295 (13):1519-30. (Medline). Giraldez RR, Nicolau JC, Korbalan R, et al. Enoxaparin outperforms unfractionate heparin in patients with myocardial infarction ST height, undergoing fibrinolism regardless of the choice of lítica: analysis exTRACT-TIMI 25. *Eur Heart J*. 2007 Jul. 28 (13):1566-73. (Medline). Vallentin L, Goldstein P, Armstrong PW, et al. Efficiency and Safety of Tenecteplase combined with low-myoacular-weighted enoxaparin or unfractional heparin in pre-post-tilt setting: Assessment of the safety and efficacy of the new thrombolytic regimen (ASSENT)-3 PLUS randomized study in acute myocardial infarction. *Circulation*. 2003 July 15. 108 (2):135-42. (Medline). Assessment of the safety and efficacy of the new thrombolytic regimen (ASSENT)-3 Investigators. Efficiency and safety of tenecteplase in combination with enoxaprine, aciximab, or unfractional heparin: RANDOMISYROVAL study ASSENT-3 in acute myocardial infarction. *Lancet*. 2001 Aug 25. 358 (9282):605-13. (Medline). White H, Hirsulog and Early Reperfusion or Occlusion (HERO)-2 Forensic Investigators. Trombromin-specific anticoagulation with bivalirudin against heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: HERO-2 randomized trial. *Lancet*. 2001 Dec 1. 358 (9296):1855-63. (Medline). Henriksson R., Bjorklund F, Mu T. Introduction of ticagrelor is associated with lower rates of recurrent ischemic stroke after acute myocardial infarction. *PLoS one*. 2019. 14 (5):e0216404. (Medline). Wiviott SD, Brownwald E, McCabe CH, et al. for TRITON-TIMI 38 investigators. Prasugrel vs. clopidogrel in patients with koronarnymi sindromami. *N Engl J Med*. 2007 - 15. 357 (20):2001-15. (20):2001-15. Tchng JE, Mackay SM. Prasugrel vs. clopidogrel antithrombotic therapy after acute coronary syndrome: matching treatment with patients. *Am J Cardiovasc Drugs*. 2012 Apr 1. 12 (2):83-91. (Medline). Schnapf AJ. Prasugrel vs. clopidogrel: new strategies for managing acute coronary syndrome. *J Cardiovasc nurse*. 2013 September-October. 28 (5):483-94. (Medline). Ryan T.J. Percutaneous coronary intervention in myocardial infarction. *Curr Cardiol Republic* 2001 July 3(4):273-9. (Medline). Berger JS, Sallum RH, Cato B, et al. Is there a link between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of literature. *Am Heart J*. 2012 Aug. 164 (2):153-162.e5. (Medline). CURRENT-OASIS 7 Investigators. Mehta SR, Bassand JP, Chrolavicius S, et al. Comparison of clopidogrel doses and aspirin in acute coronary syndromes. *N Engl J Med*. 2010 Sep 2. 363 (10):930-42. (Medline). CAPRIE Steering Committee. Randomized, blinded, clopidogrel trial against aspirin in patients at risk of isha events (CAPRIE). *CAPRIE Steering Committee*. *Lancet*. 1996 November 16. 348 (9038):1329-39. (Medline). Wallentin L, Becker RC, Budaj A, et al., for PLATO investigators. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2009 Sep 10. 361 (11):1045-57. (Medline). Storey RF, Becker RC, Harrington RA, et al. Characteristics of shortness of breath in PLATO studies of patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. *Eur Heart J*. 2011 Dec 32 (23):2945-53. (Medline). POGON forensic investigators. Inhibition of platelets glycoprotein IIb/IIIa with eptifibatid in patients with acute coronary syndromes. Platelets of Glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. *N Engl J Med*. 1998 Aug 13. 339 (7):436-43. (Medline). Gibson CM, Goel M, Cohen DJ, et al. Six-month angiographic and clinical follow-up treatment of patients potentially randomized to receive tyrosiban or placebo during angioplasty in the RESTORE study. A randomized study of the effectiveness of tyrosiban for results and restenosis. *J Am Coll Cardiol*. 1998 July 32 (1):26-34. (Medline). Goodman SG, Cohen M, Bigonzi F, et al. Randomized study of low molecular mass heparin (enoxaparin) against unfractional heparin in unstable coronary heart disease: annual results of the ESSENCE study. The efficiency and safety of subcutaneous enoxaparin in the non-I wave of coronary events. *J Am Coll Cardiol*. 2000 September 36 (3):693-8. (Medline). Petersen JL, Mahaffey KW, Hasselblad V, et al. Effectiveness and bleeding complications among patients of randomized enoxaparin or unfractionated heparin for antithrombinal therapy in height of acute coronary syndromes: a systematic review. *Jama*. 2004 July 7. 292 (1):89-96. (Medline). White HD, Kleiman NS, Mahaffey KW, et al. Efficiency and Safety Safety compared to non-fractional heparin in high-risk patients with a non-segment of high acute coronary syndrome. undergoes percutaneous coronary intervention in the highest yield of the new strategy of enoxaparin, revascularization and glycoprotein IIb/IIIa inhibitors (SYNERGY). *Am Heart J*. 2006 December 152 (6):1042-50. (Medline). Stone GW, McLaurin BT, Cox DA, et al. for ACUTITY investigators. Bivalirudin for patients with acute coronary syndromes. *N Engl J Med*. 2006 November 23. 355 (21):2203-16. (Medline). Goto K, Lansky AJ, Fahi M, et al. Predictors of outcomes in patients with acute coronary syndromes after angiographic sorting: Acute catheterization and urgent intervention strategy (ACUTITY). *Circulation*. 2010 Feb 23. 121 (7):853-62. (Medline). Futura/OASIS-8 Trial Group, Steg PG, Jolly SS, Mehta SR, etc. Low dose vs. standard dose of non-fractional heparin for percutaneous coronary intervention in acute coronary syndromes treated by the foundationparin: randomized study FUTURA/OASIS-8. *Jama*. 2010 Sep 22. 304 (12):1339-49. (Medline). Hilarious SS, Faxon DP, Fox C.A, et al. Effectiveness and Safety fondaparinux against enoxaparin in patients with acute coronary syndromes, treatment with glycoprotein IIb/IIIa inhibitors or thienopridina: results of the OASIS 5 (Fifth Organization for Evaluation Strategies in Ischemic Syndrome) trials. *J Am Coll Cardiol*. 2009 July 28. 54 (5):468-76. (Medline). Garg R, Yusuf S. Review of randomized trials of enzyme inhibitors that convert angiotensin, about mortality and morbidity in patients with heart failure. Joint group on testing ACE inhibitors. *Jama*. 1995 May 10. 273 (18):1450-6. (Medline). Yusuf S, Sleight P, Pogue J, Davies R, Dagenais G. Effect of angiotensin-conversion enzyme, ramyprile, on cardiovascular events in high-risk patients. *Heart Results Prevention Assessment Research Researchers*. *N Engl J Med*. 2000 Jan 20. 342 (3):145-53.

